Then David, who leads the Factor XI clinical program at Regeneron, will present preclinical data as well as clinical data from the ROXI-VTE-I and II studies in venous thromboembolism prevention post ...

Q3 2025 Earnings Call Transcript November 14, 2025 P3 Health Partners Inc. misses on earnings expectations. Reported EPS is $ ...

Dr. Joshua Sabari sat down with Dr. Michael Cecchini to discuss advances in colorectal cancer management and key data ...

ANTLER phase 1 data demonstrate efficacy and durability on par with autologous CAR-T cell therapy and safety allows for ...

Late-breaking results from clinical trials, debates about lifestyle choices and cardiovascular risk, and improving clinical care with generative AI are among the topics being presented by UC San ...

The rapid development and integration of artificial intelligence (AI), including predictive, generative, and emerging agentic ...

Q3 2025 Earnings Call Transcript November 13, 2025 Operator: Greetings. Welcome to the PDS Biotechnology Corporation’s Third Quarter 2025 Earnings Conference Call. At this time, all participants are ...

Operator: Good afternoon, ladies and gentlemen, and welcome to the CytoSorbents Corp. Third Quarter 2025 Earnings Conference ...

Overview of the Digital Pathology MarketThe global Digital Pathology Market is projected to register a growth rate of approximately 10.5% by 2029. The increasing burden of chronic diseases such as ...

Discusses Advanced Wound Care Solutions and Data-Driven Approaches in Clinical Healing November 12, 2025 5:00 PM ...

FDA Fast Track designation -- The BRTX-100 program was granted Fast Track status by the FDA for chronic lumbar disc disease ...

Relmada Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.30404 EPS, expectations were $-0.04. Operator ...